Selective elimination of malignant cells from bone marrow by bis

Details Selective elimination of malignant cells from bone marrow by bis Selective elimination of malignant cells from bone marrow by bis

1989-04-06

1991-10-08

Nutter, Nathan M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

514118, 514121, 514129, 514131, A01N 4716, A01N 4102, A01N 3734

Patent

active

050554590

ABSTRACT:
A method for purging tumor cells from bone marrow of a host, the method comprising

REFERENCES:
patent: 4841085 (1980-06-01), Farquhar et al.
Filoslav Beran, Borje S. Andersson, Yugiang Wang, Kenneth B. McCredie, and David Farquhar: Cancer research 48, 339-345, Jan. 15, 1988. The Effects of Acetaldophosphamide, a Novel Stable Aldophosphamide Analogue, n Normal Human and Leukemic Progenitor Cells in Vitro: Implications for Use in Bone Marrow Purging.
A. Takamizawa et al.: Journal of the American Chemical Society, vol. 95, No. 3, 7 Feb. 1973. "Studies on cyclophosphamide metabolites and their related compounds. II. Preparation of an active species."
International Search Report for PCT/US 89/01214.
Sladek (1973), Cancer Res., 33:1150.
Conners, et al. (1974), Biochemical Pharmacol., 23:115.
Cox, et al. (1975), Cancer Res., 35:3755.
Friedman, et al. (1979), Adv. Cancer Chemother., 1:143.
Sharkis, et al. (1980), Blood, 55:521.
Korbling, et al. (1982), Brit. J. Haematol., 52:89.
Hilton, et al. (1984), Proc. Amer. Assoc. Cancer Res.
Hilton, (1984), Biochem. Pharmacol., 33:1867.
Hilton, (1984) Cancer Res., 44:5156.
Sladek, et al. (1985), Cancer Res., 45:1549.
Stewart, et al. (1985), Exp. Hematol, 13:267.
Struck, et al. (1975), Heyden and Son, Ltd.
Norpoth, (1976), Cancer Treatment Reports, 60:437.
Peter, et al. (1976), Cancer Treatment Reports, 60:429.
Struck, (1976), Cancer Treatment Reports, 60:317.
Frei, et al. (1977), Cancer Treatment Reports, 61:1209.
Farquhar, et al. (1979), J. of Labelled Compounds and Radiopharmaceuticals, XVI:615.
Farquhar, et al. (1980), J. Labelled Compounds and Radiopharmaceuticals, XVII:159.
Zon, et al. (1982), J. Pharm. Sci., 71:443.
Farquhar, et al. (1983), J. Med. Chem., 26:1153.
Farquhar, et al. (1983), J. Pharmaceutical Sciences, 72:324.
Garattini, (1983), European J. of Drug Metabolism and Pharmacokinetics, 8:97.
Struck, et al., (1983), Brit. J. Cancer, 47:015-026.
Herve', (1984), Investigational New Drugs, 2:245.
Struck and Alberts, (1984), Cancer Treatment Reports, 68:765.
de Jong, et al., (1985), Cancer Res., 45:4001.
Gordon, et al. (1985), Leukemia Research, 9:1017.
Kohn and Sladek, (1985), Biochem. Pharmacol., 34:3465.
Smith and Sladek, (1985), Biochem. Pharmacol., 34:3459.
Yeager, et al., Jul. 17, 1986, The New England Journal of Medicine, vol. 315.
Kohn, (1987), Cancer Res. 47:3180.
Montgomery and Struck, (1976), Cancer Treatment Rep., 60:381.
Struck, (1974), Cancer Res., 34:2933.

Affiliated with

Also associated with

Rating

Selective elimination of malignant cells from bone marrow by bis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selective elimination of malignant cells from bone marrow by bis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective elimination of malignant cells from bone marrow by bis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-257124